Chemistry:Funapide

From HandWiki

Funapide (INN; former developmental codes TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.[1][2][4] Funapide was evaluated in humans in both oral and topical formulations, and as of July 2014, had reached phase IIb clinical trials.[1][3] Development of the drug was discontinued in 2022.[5]

See also

References

  1. ↑ 1.0 1.1 1.2 "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters 24 (16): 3690–3699. August 2014. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923. 
  2. ↑ 2.0 2.1 "Anticonvulsants: Clinical". Wall & Melzack's Textbook of Pain (6 ed.). Elsevier Health Sciences. 2013. p. 508. ISBN 978-0-7020-4059-7. OCLC 1008841684. https://books.google.com/books?id=bNlvQJSqrB8C&q=XEN402. 
  3. ↑ 3.0 3.1 "TV-45070: A Small Molecule for the Treatment of the Orphan Disease EM and Other Pain Disorders". Xenon Pharma. http://www.xenon-pharma.com/product-candidates/pain/pain-teva/. 
  4. ↑ 4.0 4.1 "Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402". Xenon Pharma. 11 December 2012. http://www.xenon-pharma.com/2012/12/teva-and-xenon/. 
  5. ↑ "Funapide - Flexion Therapeutics". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800025125. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Funapide&oldid=4176221"